An investigational presbyopia treatment met primary efficacy endpoints in two phase 3 clinical trials, reaching statistical significance in near vision improvement, according to a press release.
AGN-190584 ophthalmic solution (pilocarpine 1.25%, Allergan) demonstrated positive topline results in the GEMINI 1 and 2 clinical trials, in which 750 patients were randomly assigned in a one-to-one ratio to receive AGN-190584 or placebo bilaterally once daily for 30 days.
In GEMINI 1, a significantly greater proportion of participants treated with AGN-190584 than vehicle gained three lines or more in
Uncategorized